[go: up one dir, main page]

NO20070330L - Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser - Google Patents

Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser

Info

Publication number
NO20070330L
NO20070330L NO20070330A NO20070330A NO20070330L NO 20070330 L NO20070330 L NO 20070330L NO 20070330 A NO20070330 A NO 20070330A NO 20070330 A NO20070330 A NO 20070330A NO 20070330 L NO20070330 L NO 20070330L
Authority
NO
Norway
Prior art keywords
methods
treatment
retinal derivatives
visual disorders
derivatives
Prior art date
Application number
NO20070330A
Other languages
English (en)
Other versions
NO339969B1 (no
Inventor
Krzysztof Palczewski
Mathew Batten
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NO20070330L publication Critical patent/NO20070330L/no
Publication of NO339969B1 publication Critical patent/NO339969B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparater av og fremgangsmåter for anvendelse av syntetiske retinalderivater som retinoiderstatninger og opsinagonister er tilveiebrakt.
NO20070330A 2004-06-18 2007-01-17 9-cis-retinalderivat og anvendelse derav ved fremstilling av et medikament eller et farmasøytisk preparat for anvendelse ved behandling av synsforstyrrelser. NO339969B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (2)

Publication Number Publication Date
NO20070330L true NO20070330L (no) 2007-03-15
NO339969B1 NO339969B1 (no) 2017-02-20

Family

ID=35782277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070330A NO339969B1 (no) 2004-06-18 2007-01-17 9-cis-retinalderivat og anvendelse derav ved fremstilling av et medikament eller et farmasøytisk preparat for anvendelse ved behandling av synsforstyrrelser.

Country Status (26)

Country Link
US (8) US7951841B2 (no)
EP (5) EP2397131B1 (no)
JP (2) JP5166026B2 (no)
KR (4) KR20140140616A (no)
CN (2) CN1988898B (no)
AU (1) AU2005257997B2 (no)
BR (1) BRPI0511396B1 (no)
CA (2) CA2571049C (no)
CY (2) CY1114873T1 (no)
DK (2) DK1765322T3 (no)
ES (4) ES2443194T3 (no)
HR (1) HRP20140116T1 (no)
HU (1) HUE036596T2 (no)
IL (4) IL180078A (no)
IN (1) IN2012DN09335A (no)
LT (1) LT2397133T (no)
MX (2) MX359668B (no)
NO (1) NO339969B1 (no)
NZ (2) NZ587006A (no)
PL (2) PL2397133T3 (no)
PT (2) PT1765322E (no)
RS (1) RS53178B (no)
RU (2) RU2408578C2 (no)
SI (2) SI1765322T1 (no)
WO (1) WO2006002097A2 (no)
ZA (1) ZA200700368B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610772A4 (en) 2003-03-14 2008-06-18 Univ Washington RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF
RU2408578C2 (ru) 2004-06-18 2011-01-10 Юниверсити Оф Вашингтон Производные ретиналя и способы их применения для лечения нарушений зрения
NZ551955A (en) 2004-06-23 2010-08-27 Revision Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
JP4178281B2 (ja) * 2004-12-08 2008-11-12 シリオン セラピューティクス， インコーポレイテッド レチノール関連疾患を処置するための方法、アッセイおよび組成物
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CA2657238A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
US8338394B2 (en) * 2006-10-12 2012-12-25 Case Western Reserve University Methods for treating metabolic diseases
RU2494089C2 (ru) 2007-04-20 2013-09-27 Акьюсела Инк. Соединения, представляющие собой стиролильные производные, для лечения офтальмических заболеваний и расстройств
NZ587376A (en) * 2008-02-11 2012-06-29 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
JP5443470B2 (ja) * 2008-04-29 2014-03-19 株式会社日健総本社 眼障害の治療方法
IN2012DN00352A (no) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CA2774168C (en) * 2009-09-15 2021-02-23 Ronald Erwin Boch Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
SG10201507819VA (en) * 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
WO2012061690A2 (en) * 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
CA2865935C (en) * 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
JP7067843B2 (ja) * 2016-04-28 2022-05-16 スパーク セラピューティクス インコーポレイテッド イソメロヒドロラーゼをコードするウイルスベクターについての相対効力アッセイ
US20250161254A1 (en) * 2022-02-04 2025-05-22 New York University Use of retinoids for treatment of atrial fibrillation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) * 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
WO1995026734A1 (en) 1994-04-04 1995-10-12 Freeman William R Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) * 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
NZ306694A (en) * 1995-04-03 2000-01-28 Johnson & Johnson Consumer Skin care composition containing a retinoid
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
AU785285B2 (en) 2000-03-10 2006-12-21 Sun Pharma Global Fze Methods and compositions for treating and preventing posterior segment ophthalmic disorders
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
JP4210115B2 (ja) * 2001-01-11 2009-01-14 チェビジェン・インコーポレイテッド 新規レチノール誘導体および製造方法および用途
CA2435410A1 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
JP2005524626A (ja) 2002-01-18 2005-08-18 タットン テクノロジーズ エルエルシー． 眼疾患を治療するための方法
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CA2480047A1 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
EP1610772A4 (en) 2003-03-14 2008-06-18 Univ Washington RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF
BRPI0507807A (pt) 2004-02-17 2007-07-31 Harvard College gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CN1964706A (zh) 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
RU2408578C2 (ru) 2004-06-18 2011-01-10 Юниверсити Оф Вашингтон Производные ретиналя и способы их применения для лечения нарушений зрения
NZ551955A (en) 2004-06-23 2010-08-27 Revision Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
US8877809B2 (en) 2007-09-12 2014-11-04 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
NZ587376A (en) 2008-02-11 2012-06-29 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
HRP20140116T1 (hr) 2014-03-28
ZA200700368B (en) 2008-10-29
LT2397133T (lt) 2018-01-10
EP2397132A2 (en) 2011-12-21
JP5166026B2 (ja) 2013-03-21
MX359668B (es) 2018-10-05
CN1988898A (zh) 2007-06-27
RU2408578C2 (ru) 2011-01-10
US20110288170A1 (en) 2011-11-24
US9174936B2 (en) 2015-11-03
EP1765322A2 (en) 2007-03-28
DK1765322T3 (da) 2014-02-10
EP2397131A3 (en) 2012-10-31
IL230242A (en) 2015-10-29
BRPI0511396A (pt) 2007-12-04
IL180078A (en) 2014-01-30
KR20130079669A (ko) 2013-07-10
RS53178B (sr) 2014-06-30
EP2397133A3 (en) 2012-07-11
MXPA06014750A (es) 2007-03-21
IL230241A (en) 2015-06-30
EP2397130A2 (en) 2011-12-21
IL222347A (en) 2017-08-31
JP2008503496A (ja) 2008-02-07
KR101490145B1 (ko) 2015-02-05
EP2397133B1 (en) 2017-07-26
IL180078A0 (en) 2007-05-15
ES2443194T3 (es) 2014-02-18
US7951841B2 (en) 2011-05-31
US20130072560A1 (en) 2013-03-21
CA2571049C (en) 2016-08-09
PT1765322E (pt) 2014-02-05
IN2012DN09335A (no) 2015-08-21
JP2012229234A (ja) 2012-11-22
US20130079403A1 (en) 2013-03-28
US20190167626A1 (en) 2019-06-06
EP2397132A3 (en) 2012-07-11
ES2644981T3 (es) 2017-12-01
HUE036596T2 (hu) 2018-07-30
PL2397133T3 (pl) 2018-01-31
BRPI0511396B1 (pt) 2021-07-27
CN1988898B (zh) 2012-12-26
US9169204B2 (en) 2015-10-27
NZ587006A (en) 2011-12-22
CN102976937B (zh) 2016-12-21
ES2644984T3 (es) 2017-12-01
US10117845B2 (en) 2018-11-06
RU2010138410A (ru) 2012-03-27
WO2006002097A2 (en) 2006-01-05
AU2005257997B2 (en) 2012-04-05
SI2397133T1 (sl) 2017-12-29
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
EP1765322B1 (en) 2013-11-06
NO339969B1 (no) 2017-02-20
PL1765322T3 (pl) 2014-04-30
HK1098696A1 (en) 2007-07-27
KR20140140616A (ko) 2014-12-09
AU2005257997A1 (en) 2006-01-05
CA2931917A1 (en) 2006-01-05
US9403765B2 (en) 2016-08-02
CY1114873T1 (el) 2016-12-14
CY1119480T1 (el) 2018-03-07
EP2397131A2 (en) 2011-12-21
KR20070026817A (ko) 2007-03-08
CN102976937A (zh) 2013-03-20
EP2397131B1 (en) 2019-09-11
EP2397133A2 (en) 2011-12-21
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
EP2397130A3 (en) 2012-10-31
US20170014368A1 (en) 2017-01-19
US9162978B2 (en) 2015-10-20
KR101323122B1 (ko) 2013-10-30
US20130072559A1 (en) 2013-03-21
SI1765322T1 (sl) 2014-03-31
US9388130B2 (en) 2016-07-12
JP5596749B2 (ja) 2014-09-24
CA2571049A1 (en) 2006-01-05
NZ552080A (en) 2011-03-31
PT2397133T (pt) 2017-10-23
WO2006002097A3 (en) 2006-05-04
EP1765322A4 (en) 2008-09-17
RU2007101735A (ru) 2008-07-27
US20130072556A1 (en) 2013-03-21
US20080221208A1 (en) 2008-09-11
EP2397130B1 (en) 2019-04-03
ES2752924T3 (es) 2020-04-06
RU2554003C2 (ru) 2015-06-20

Similar Documents

Publication Publication Date Title
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
NO20065179L (no) Polysykliske pyridiner som kalsium-kanalmodulatorer
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
CR11731A (es) Composiciones y procedimientos para su preparación y uso
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
WO2006030439A3 (en) Compositions and methods for inducing hair growth
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MY135829A (en) Analeptic and drug combinations
EP4585213A3 (en) Amlodipine formulations
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
TW200507840A (en) Method of treating multiple myeloma
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ
NO20082838L (no) 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees